Overview

• Semaglutide injections reduce the risk of severe kidney events by 24% in patients with chronic kidney disease and type 2 diabetes.
• The drug also lowers the risk of major cardiovascular events by 18% and all-cause mortality by 20%.
• Research indicates benefits extend to patients without diabetes, suggesting broader applications for kidney protection.
• Experts highlight potential economic impacts, with reduced healthcare costs and improved patient outcomes.
• The findings support expanding the use of semaglutide for treating multiple chronic conditions.